Nicolas Margot

机构：Gilead Sciences (Spain), Gilead Sciences (United States) · ORCID：0000-0002-0911-4237

发表论文 95 篇 · 总被引 4541 次 · h-index 38

代表论文

• Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection (2022 · New England Journal of Medicine · 被引 312)
• Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial (2023 · The Lancet HIV · 被引 71)
• Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes (2020 · Antimicrobial Agents and Chemotherapy · 被引 66)
• Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir (2022 · The Journal of Infectious Diseases · 被引 57)
• Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study (2022 · Journal of Antimicrobial Chemotherapy · 被引 56)
• Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial (2024 · Clinical Infectious Diseases · 被引 37)